Japan's Takeda committed
to single-digit U.S. drug price rises
Send a link to a friend
[February 01, 2017]
TOKYO (Reuters) - Japan's largest
drugmaker, Takeda Pharmaceuticals Co, on Wednesday said it would
maintain its pricing model in the U.S. market, brushing off demands by
U.S. President Donald Trump for drugmakers to offer cheaper drugs.
|
"Takeda has for many years been reasonable in its price increases in
the U.S. and we are very committed to single-digit price increase,"
Takeda Chief Executive Christophe Weber told reporters at a results
briefing.
Trump has called on global pharmaceutical companies to make more of
their drugs in the United States and cut prices.
Takeda, which produces cancer treatments including Velcade, which
targets a type of blood cancer, earns around a third of its drugs
revenues from the United States, its biggest market outside Japan.
After picking up cancer drug maker Ariad Pharmaceuticals Inc in a
$5.2-billion deal this month, the company said it was looking for
more acquisitions to bolster its drug portfolio and expand to more
overseas markets.
(Reporting by Naomi Tajitsu; Editing by Clarence Fernandez)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
![](http://archives.lincolndailynews.com/2017/Jan/26/images/ads/current/Symphony_lda_2017.png)
![](http://archives.lincolndailynews.com/2017/Feb/01/images/ads/current/graue_17_cruze_110716.png)
|